Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through in vitro experiments related to xanthine oxidase. This study plans to recruit patients with hyperuricemia who visit the clinical nutrition department and rheumatology and immunology department of Peking University People's Hospital, randomly dividing them into an intervention group and a control group. The intervention group will take barley green plus a balanced diet plan, while the control group will only be given a balanced diet plan. General clinical data will be collected, and nutritional measurements will be conducted. Venous blood will be drawn for the determination of uric acid metabolism-related indicators, xanthine oxidase activity, and inflammatory factor levels. The differences in uric acid and related metabolic indicators, as well as xanthine oxidase activity, between the two groups will be observed and compared to provide a scientific basis for the clinical application of barley green in non-pharmacological intervention and medical nutrition therapy for hyperuricemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control group | No Intervention | ||
| intervention group | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| barley green | Dietary Supplement | Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day |
|
| Measure | Description | Time Frame |
|---|---|---|
| uric acid levels in umol/L | Uric acid levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Xanthine oxidase activity in ng/mL | Xanthine oxidase activity was measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| erythrocyte sedimentation rate in mm/h |
Not provided
Inclusion Criteria:
Exclusion Criteria:
① Patients currently receiving drug treatment for hyperuricemia;
Patients with diseases affecting food digestion and absorption (such as chronic diarrhea, constipation, severe digestive tract inflammation, active peptic ulcers, post-gastrointestinal resection, cholecystitis/cholecystectomy, etc.);
Patients with cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia (hemoglobin value below the normal reference range), mental disorders and memory impairment, epilepsy, etc.;
Patients simultaneously receiving other functional food nutritional support (plant active substances, health foods);
Patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeding 3 times the upper limit of the normal value); patients with abnormal kidney function (serum creatinine exceeding the upper limit of the normal value);
Patients with active pulmonary tuberculosis, AIDS and other infectious diseases; ⑦ Patients with severe allergies to the ingredients of the study nutritional product;
Pregnant or lactating women;
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University People's Hospital | Beijing | Xicheng District | 100044 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41245398 | Derived | Cui M, Shao L, Zhao S, Guo Q, Liu X, Liu P. Effects of barley green on uric acid, inflammatory factors, xanthine oxidase activity and body composition of patients with hyperuricemia: a randomized controlled trial. Front Nutr. 2025 Oct 31;12:1684829. doi: 10.3389/fnut.2025.1684829. eCollection 2025. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Erythrocyte sedimentation rates were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. |
| From enrollment to the end of treatment at 12 weeks |
| antinuclear antibody in semi-quantitative | Antinuclear antibodies were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| blood glucose in mmol/L | Blood glucoses were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| total cholesterol in mmol/L | Total cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| triglycerides in mmol/L | Triglycerides were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| high-density lipoprotein cholesterol in mmol/L | High-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| low-density lipoprotein cholesterol in mmol/L | Low-density lipoprotein cholesterols were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| C-reactive protein in mg/L | C-reactive proteins were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| white blood cell count in 10^9/L | White blood cell counts were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| leptin level in pg/mL | Leptin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| adiponectin level in ug/mL | Adiponectin levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IL-1β in pg/mL | IL-1β levels were measured by blood samples at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IL-2 in pg/mL | IL-2 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IL-4 in pg/mL | IL-4 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IL-6 in pg/mL | IL-6 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IL-10 in pg/mL | IL-10 levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| IFN-γ in pg/mL | IFN-γ levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| TNF-α in pg/mL | TNF-α levels were measured by blood samples at two time points: the day of enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| height in centimeters | Height in centimeters were measured by Manual Height Ruler at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| weight in kilograms | Weight in kilograms were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| BMI in kg/m^2 | Weight and height will be combined to report BMI in kg/m^2 at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| body fat rate in % | Body fat rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| muscle mass in kilograms | Muscle masses were measured by were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| basal metabolic rate in kcal | Basal metabolic rates were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| skeletal muscle mass in kilograms | Skeletal muscle masses were measured by the Inbody 770 instrument at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| blood pressure in mmHg | Blood pressures were measured by electronic blood pressure monitor at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| waist circumference in millimeters | Waist circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| hip circumference in millimeters | Hip circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| upper arm circumference in millimeters | Upper arm circumferences were measured by tape measure at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| left hand grip strength in pound-force | Left hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| right hand grip strength in pound-force | Right hand grip strengths were measured by grip dynamometer at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| triceps skinfold thickness in millimeters | Triceps skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| subscapular horn skinfold thickness in millimeters | Subscapular horn skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| abdominal skinfold thickness in millimeters | Abdominal skinfold thicknesses were measured by skin fold thickness gauge at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |
| food intake dose in grams | Data of food intake doses were taken by food frequency questionnaire and 3-day food diary at four time points: the day of enrollment, 4 weeks after enrollment, 8 weeks after enrollment and 12 weeks after enrollment. | From enrollment to the end of treatment at 12 weeks |